Immunovant Inc
IMVTHealthcare|Biotechnology|USA
$39.71
-1.38 (-3.36%)
Tangible Book
$4.18
Earnings Power
$4.41
About
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Stock Price
+126.9%(1Y)
Pipeline Summary
19 total trials0
Phase 1
14
Phase 2
5
Phase 3
0
Phase 4
Recruiting: 5Active: 4Completed: 5ENROLLING_BY_INVITATION: 2Terminated: 3
Active Trials (9)
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916Generalized Myasthenia Gravis
Phase 3Recruiting
Enrollment: 231 participants
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus
Phase 2Active
Enrollment: 56 participants
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
NCT05581199Chronic Inflammatory Demyelinating Polyneuropathy
Phase 2Active
Enrollment: 277 participants
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323Graves' Disease
Phase 2Recruiting
Enrollment: 210 participants
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
Phase 2Recruiting
Enrollment: 240 participants
BioScore
5.1/10
Watchlist
Ownership
Recent Insider Trades
Gloria MelanieSELL
2026-07-082,036 shares @ $39.55
Van Tuyl ChristopherSELL
2026-07-081,206 shares @ $39.55
Stout Jay SSELL
2026-07-083,487 shares @ $39.55
Venker EricSELL
2026-07-023,092 shares @ $38.48
Gloria MelanieSELL
2026-06-2617,714 shares @ $38.31
Recent News
2026-06-30 19:32:39
2026-06-27 02:00:48
Data last updated: Jul 12, 2026, 07:36 PM